Global Clinical Specialist
An open-label, multi-center, prospective clinical trial was performed among 78 PCR-confirmed COVID-19 patients admitted to the ICU with severe or life-threatening symptoms. Convalescent plasma therapy combined with standard treatment (n = 28) was compared to standard treatment alone (n = 50), stratified by disease severity.
In combination with standard treatment, CP therapy resulted in 78% reduction of 28-day ICU mortality (HR = 0.22) compared to standard treatment alone. Also, other significant indicators of the treatment effect of CP show that this novel CP production method was effective and represents a practical solution for low and middle-income countries to produce CP locally.
Hemoclear joins forces with VDL HemoClear joins forces with VDL in manufacturing the HemoClear autologous blood filter. The Dutch innovation HemoClear is t
In the strategic ambition to optimize production, increase flexibility, and decrease lead times and costs, HemoClear will centralize all production
As a proud sponsor, HemoClear attended the Bloodless Medicine and Surgery Society Annual Meeting. At the event Dr Rosita Bihariesingh presented a case of s